Top Tweets for #TBCPartner
Congratulations to #TBCPartner @AtalantaTx who just announced an oversubscribed Series B financing of $97 million! The funding will support the advancement of Atalanta's RNAi medicines for CNS diseases, including clinical development for its investigational therapies targeting KCNT1-related epilepsy and Huntington’s disease.
Named after the Greek heroine Atalanta, the company was founded to promote RNA interference that could silence disease-causing genes. This Nobel prize-winning science offers an opportunity to regulate genes and stop disease at its source.
We can't wait to see what the future holds for this motivated team.
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic. https://t.co/I9w4VVNcWa
#TBCPartner @intelliatx presented the first disease progression data from its Phase 1 trial of nex-z in transthyretin amyloidosis, an underappreciated cause of heart failure in elderly patients, during a special scientific session in Chicago this weekend to celebrate the 100th anniversary of the American Heart Association (@American_Heart).
The data showed that nex-z has real potential to halt or even reverse the course of disease. With Phase 3 trials underway, we look forward to learning more about what Intellia’s revolutionary #CRISPR therapies can do for patients.
Intellia says its gene editing treatment for a heart muscle disease can stabilize or improve outcomes where other treatments have only been shown to slow the disease’s progression.
https://t.co/HAUUNtfzT1
#TBCPartner Archon Biosciences is coming out of stealth with $20M in seed financing at an incredibly exciting time.
As this year’s Nobel Prize in Chemistry highlights, advances in protein design have created myriad of possibilities for improving human health. Archon is taking one of the most direct routes of applying this new technology by using generative protein design to transform antibodies into more effective drugs.
We’re thrilled for the Archon team and join them in celebrating this momentous occasion! Learn more about their science and team at https://t.co/yB0QoVlcSB
The newest David Baker startup is taking an AI twist on antibodies to make a new therapeutic modality, antibody cages
$20 million seed round to start: https://t.co/FzhQQvg43K
Today #TBCPartner @SeaportTx , a founded entity of fellow #TBCPartner @PureTechH has successfully closed a Series B financing of $225 million led by @generalatlantic to progress its clinical-stage pipeline of neuropsychiatric medicines. Seaport is focusing on programs for major depressive disorder, generalized anxiety and mood disorders, one of the most challenging therapeutic areas for drug development.
Today we announced a $225M oversubscribed Series B led by @generalatlantic. Proud to partner w/an incredible group of investors who share our commitment of delivering better medicines to those w/ #depression, #anxiety & other #neuropsychiatric disorders: https://t.co/o9ZvAUQron
Congrats to #TBCPartner @PureTechH on the FDA approval of Cobenfy (formerly KarXT), originally invented by the team at PureTech! This drug marks the first new innovation for the treatment of #schizophrenia in over 50 years.
Read more: https://t.co/5Q3BfeG9Dz
#TBCPartner AIRNA today announced the successful closing of an oversubscribed $60 million financing round, an important step forward for their work to advance a broad RNA editing pipeline, including their lead program for alpha-1 antitrypsin deficiency (AATD). Read more in today’s piece by @AlexWestchester at @GENbio:
RNA Editing Therapy Developer Closes $60M Series A Financing
AIRNA, a developer of RNA editing therapies whose lead program targets AATD, has closed an oversubscribed $60 million Series A financing. Learn more: https://t.co/PNRhICpYKY
Earlier this year, we had the privilege of partnering with #TBCPartner Clasp Therapeutics to launch their company and announce their Series A. Clasp is developing off-the-shelf precision immuno-oncology therapeutics to target hard-to-treat tumors with absolute specificity. Their launch was incredibly impactful, receiving some great recognition across key media outlets. Some of the communications highlights included:
- 19 feature stories
- 37 total pieces of coverage
- Gained 2,500 LinkedIn followers in the first 24 hours following launch
Learn more about our collaboration with Clasp in our recent case study: https://t.co/pSv29DUd3Z
Tune in to the latest @Labiotech_eu to hear how #TBCPartner @MolecularPrtnrs is contributing to “The Radiotherapeutics Boom.” CEO Patrick Amstutz and SVP Research and Technology Daniel Seiner talk with host Jim Cornall and radiopharmaceutical expert Ken Herrmann about Molecular Partners’ #RadioDARPin platform, their preclinical data and the future of the field.
The field of radiotherapeutics is a hot topic currently. Listen to our conversation with three experts in the field. https://t.co/imHTM8z4g1
#TBCPartner @X4Pharma's momentum continues with the announcement of interim data from its ongoing Phase 2 trial of mavorixafor, the company’s oral CXCR4 antagonist, in chronic neutropenia. Chronic neutropenia is a rare condition in which patients’ low levels of neutrophils in the blood lead to higher risk of developing infections and reduced quality of life. It’s exciting to see progress toward a new treatment option for these patients.
Today, we announced positive interim Phase 2 data for our product candidate in #ChronicNeutropenia (CN) and have started screening patients for our Phase 3 clinical trial in CN. Join our webinar at 8:00 am ET for details. Learn more here: https://t.co/bAzuSG2QJy
#TBCPartner @intelliatx continues to push the boundaries of #CRISPR genome editing. While the goal of their therapies in development is to be one-and-done, new data suggest that the editing technology can potentially be redosed, which may have advantages in certain contexts.
Can #CRISPR be given twice? Small study from @intelliatx suggests it can.
But why would you want a CRISPR therapy twice? Isn't this supposed to be one-and-done? Yes, but there are some cases where 2 or 3 doses could help. My story for @endpts explains:
https://t.co/xHYRe3w0j2
We want to extend our congratulations to #TBCPartner @Sarepta and the entire Duchenne community on last night’s monumental FDA decision. With the expanded label, Sarepta’s gene therapy is now approved for the majority of patients with Duchenne muscular dystrophy.
BREAKING: Today, we announced the U.S. FDA has expanded the product label for our gene therapy and more people may be able to receive treatment.
Intended for U.S. audiences
Congrats to #TBCPartner Rapports Therapeutics on their $154M IPO. We can’t wait to see how their RAP-based platform leads to new possibilities in addressing CNS disease.
🎊 Welcome to the #NasdaqListed family, Rapport Therapeutics!
💊 $RAPP is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system disorders. #RapportIPO
Another important milestone for #TBCPartner @intelliatx, who announced positive long-term data from its in vivo Phase 1 study of NTLA-2002 for hereditary angioedema (HAE). NTLA-2002 continues to show durable reduction of monthly attack rates with just a single dose, and potential to be a functional cure for people living with this rare disease. Fantastic progress for in vivo gene editing, the field of genomic medicine and #CRISPR technology!
Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at @EAACI_HQ 2024 Congress. Full details here: https://t.co/HApgVmi8ds
#HAE #CRISPR #geneediting
#TBCPartner FogPharma is growing their pipeline and expanding into the highly promising area of #radiopharmaceuticals via their new collaboration with @artbio_inc. We were proud to partner with Fog on this important milestone. Congrats, Fog and ARTBIO teams! We’re excited to see these programs take shape.
FogPharma, Artbio join forces to design a different radiopharma drug https://t.co/ffSmwlp4Se by @NedPagliarulo
It’s a very exciting day for #TBCPartner @X4Pharma, who received #FDAApproval for the first drug to address the underlying cause of the rare immunodeficiency known as WHIM syndrome.
Days like today are a crystallization of why we love what we do — supporting companies who are delivering innovation and hope for patients. Congratulations to the X4 team!
@leilei_wuu @endpts
https://t.co/bh4Ljz91cO
Wonderful news for #TBCPartner @PureTechH on the successful launch of @SeaportTx! Backed by a $100 million Series A financing round with support from top biotech investors including ARCH Venture Partners, @SofinnovaVC and @ThirdRockV, Seaport is rapidly advancing a clinical-stage pipeline of first and best-in-class medicines in the #neuropsychiatric space.
Learn more about the announcement from @ky_lahucik's coverage in @endpts:
PureTech creates another neuro biotech, called Seaport Therapeutics, after success w/Karuna
more on its $100M launch, including interviews w/CEO @daphnezohar about the personal mission & w/chair Steve Paul, who “failed retirement another time”
@endpts
https://t.co/mUc6V7iqX1
Congratulations to #TBCPartner @intelliatx who made news by dosing a patient in the first Phase 3 clinical trial of an in vivo CRISPR therapy. Read this recent article from @WSJ by Betsy McKay to learn why “in vivo is the future.”
https://t.co/LIZk49oiOK
#TBCPartner Clasp Therapeutics launched today with an impressive $150 million Series A that they will use to progress their innovative T cell engager platform to the clinic. As they work to develop novel medicines that can target tumor cells with absolute specificity, they are a company to watch in the I/O space. Congratulations!
Clasp launches with $150M and a plan for precision cancer immunotherapies https://t.co/2VtWC78MWe by @gwendolynawu
Congratulations to #TBCPartner FogPharma on the successful closing of a $145 million Series E financing with the strong backing of multiple blue chip life sciences investors. As FogPharma CEO Mathai Mammen (@mmammen) told @ADeAngelis_bio of @statnews: "Life is short. Let's try, at least, to focus on extraordinary drugs."
We couldn't be prouder to partner with the FogPharma team on this important milestone that furthers their mission: to deliver a new modality that has the potential to yield lifesaving therapies that fundamentally change how devastating diseases are treated.
Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few biotechs meet. https://t.co/97aMLxiXDa
Congratulations to #TBCPartner @intelliatx on a second publication in The New England Journal of Medicine – this time for its NTLA-2002 Phase 1 data for patients with hereditary angioedema. Great work, team!
It is an honor to have our NTLA-2002 interim phase 1 data in #HAE published in the @NEJM. We are pleased to share our findings with the medical community and want to thank all who made this recognition possible! Read more in our press release: https://t.co/927oZ5wBbw
#CRISPR #GeneEditing #hereditaryangioedema
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.4M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
87M followers
Taylor Swift
@taylorswift13
80.9M followers
Lady Gaga
@ladygaga
72.4M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
68.9M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.5M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.1M followers